SPIRIT Study: Switching to the Single-Tablet Regimen (STR) of Emtricitabine/Rilpivirine/Tenofovir DF from a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors Maintains HIV Suppression and Improves Serum Lipids
Frank Palella, MD1, Pablo Tebas, MD2, Peter Ruane, MD3, David Shamblaw, MD4, Jason Flamm, MD5, Ramin Ebrahimi, MS6, Kirsten White, PhD6, Hiba Graham, PharmD6, Mark Bernstein, RPh, MBA6 and Jason T. Hindman, PharmD, MBA6
1Northwestern University, Chicago, IL
2University of Pennsylvania, Philadelphia, PA
3Peter J. Ruane, MD, Inc., Los, Angeles, CA
4La Playa Medical Group and Clinical Research, San Diego, CA
5Kaiser Permanente, Sacramento, CA
6Gilead Sciences, Foster City, CA